Breaking News: AbbVie Files Complaint Against Amgen - Big Molecule Watch

AbbVie has filed a complaint against Amgen related to AbbVie’s Humira (adalimumab).  The complaint asserts patent infringement and also seeks a declaratory judgment to compel Amgen to comply with the BPCIA’s notice of commercial marketing provision.

Stay tuned to Big Molecule Watch for more details later today.

Download PDF